Skip to Main Content

HRSA Electronic Handbooks

Funding Cycle View

Expand

Rural Communities Opioid Response Program-Medication-Assisted Treatment Expansion

  • Program Name:Rural Communities Opioid Response Program - MAT Expansion
  • Activity Code:GA3
  • Application Available:4/25/2019
  • Application Deadline:6/18/2019
  • Created By:Schwab, Dawn
  • Created On:11/21/2018
  • Last Updated by:Wildberger, William
  • Last Updated On:6/13/2019
  • Estimated Project Start Date:9/1/2019
 
Collapse

 Details of the changes posted in this announcement

Modification published on 06/13/2019
Updated EHB for waiver

Modification published on 05/06/2019
Updated title of NOFO

Modification published on 04/30/2019
updated flag for application type

 
Collapse

 Announcement Information

Announcement Number HRSA-19-102
Announcement Code
CFDA Number 93.912
Provisional No
Activity Code GA3
Competitive Yes
Fiscal Year 2019
 
Collapse

 Purpose

The Rural Communities Opioid Response Program (RCORP) is a multi-year initiative by the Health Resources and Services Administration (HRSA) aimed at reducing the morbidity and mortality of substance use disorder (SUD), including opioid use disorder (OUD), in rural communities at the highest risk for SUD. This funding opportunity, RCORP-Medication Assisted Treatment Expansion (RCORP-MAT Expansion), will advance RCORP’s overall goal by establishing and/or expanding MAT in eligible hospitals, health clinics, or tribal organizations in high-risk rural communities. RCORP-MAT Expansion aims to increase the number of access points where individuals living in rural communities with OUD can receive evidence-based treatment. Additionally, recognizing that MAT patients may have other clinical and social service needs, RCORP-MAT Expansion requires that eligible entities provide and/or coordinate complementary services (e.g., provision of or referral to other SUD/OUD and mental health services, assistance with transportation, etc.), as outlined in the Program-Specific Instructions section of this NOFO. For the purposes of this funding opportunity, HRSA defines MAT as the use of U.S. Food and Drug Administration (FDA)-approved medications, in combination with counseling and behavioral therapies, to provide a “whole-patient” approach to the treatment of substance use disorders.1
 
Collapse

 Legislative Information

Section 711(b)(5) of the Social Security Act (42 U.S.C. 912(b)(5)), as amended; Public Law No. 115-245
 
Collapse

 Application Information

Application Available 04/25/2019
Application Deadline 06/18/2019
Supplemental Application Deadline N/A
Explanation for Deadline N/A
Archive Date 08/30/2019
Letter of Intent Not required
Application Package SF424
Allow Applications to be Reopened in EHBs No
FOA Available Yes
Competitive Application Types Supported New; Continuation & Supplement
Allow Electronic Submission N/A
Page Limit for Application
Attachments
80
Allow Multiple Applications
from an Organization from Grants.gov
No
Electronic Submission Instruction Electronic submission is/will be available in HRSA EHBs
 
Collapse

 General Information

Projected Award Date N/A
Estimated Project Period N/A
Estimated Project Start Date 09/01/2019
Estimated Project End Date 08/31/2022
Estimated Amount of this Competition $8,000,000.00
Estimated Number of Awards 11
Estimated Average Size of Awards $0.00
Cost Sharing No
Cooperative Agreement No
 
Collapse

 Contact Information

Name Kiley Diop
Email ruralopioidresponse@hrsa.gov
Phone Number (301)443-6666
 
Collapse

 Download Information

Expand FOA (Guidance) Attachment (Maximum 1)
Document Name Size Date Attached Description
HRSA 19-102 - FINAL.pdf 499 kB 04/25/2019
Expand Application Package (Maximum 1)
No documents attached
Expand User Guide (Maximum 1)
No documents attached


Scroll to top